New Huntington's drug enters first human tests
NCT ID NCT07246941
First seen Nov 24, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This early-stage study tests a new medicine called RG6496 in people who carry the gene for Huntington's disease. The main goal is to check if the drug is safe and how the body handles it. About 40 participants will receive a single dose into the spine, with some getting a placebo. After the initial part, everyone can join an open-label extension to receive the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Britanico de Buenos Aires
RECRUITINGCiudad Autonoma Bs As, C1280AEB, Argentina
-
New Zealand Brain Research Institute
RECRUITINGChristchurch, 8011, New Zealand
-
Westmead Hospital
RECRUITINGWestmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.